A comprehensive insight on the challenges for COVID-19 vaccine: A lesson learnt from other viral vaccines

[1]  T. Wu,et al.  COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection , 2022, Journal of Biomedical Science.

[2]  Vivek P. Chavda,et al.  Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world , 2022, Frontiers in Immunology.

[3]  M. Soltani,et al.  The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: A systematic review and meta-analysis , 2022, Frontiers in Public Health.

[4]  Y. Shoenfeld,et al.  Autoimmune post-COVID vaccine syndromes: does the spectrum of autoimmune/inflammatory syndrome expand? , 2022, Clinical Rheumatology.

[5]  D. Ye,et al.  New‐onset autoimmune phenomena post‐COVID‐19 vaccination , 2021, Immunology.

[6]  J. Nie,et al.  The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron , 2021, Emerging microbes & infections.

[7]  A. Mushtaq,et al.  COVID‐19 vaccinations: The unknowns, challenges, and hopes , 2021, Journal of medical virology.

[8]  B. Nogrady.  Mounting evidence suggests Sputnik COVID vaccine is safe and effective , 2021, Nature.

[9]  P. Kalra,et al.  Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine , 2021, The New England journal of medicine.

[10]  V. Jha,et al.  Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities , 2021, The Lancet Infectious Diseases.

[11]  D. Parums.  Editorial: SARS-CoV-2 mRNA Vaccines and the Possible Mechanism of Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) , 2021, Medical science monitor : international medical journal of experimental and clinical research.

[12]  G. Lawton.  Sputnik V vaccine goes global , 2021, New Scientist.

[13]  S. Panda,et al.  Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B 1.1.7 variant of SARS-CoV-2 , 2021, Journal of travel medicine.

[14]  Caixia Lu,et al.  Tree Shrew as a New Animal Model for the Study of Dengue Virus , 2021, Frontiers in Immunology.

[15]  D. Segev,et al.  Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients. , 2021, JAMA.

[16]  Vineet D. Menachery,et al.  The variant gambit: COVID-19’s next move , 2021, Cell Host & Microbe.

[17]  T. Shimabukuro,et al.  Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine. , 2021, JAMA.

[18]  K. Ella,et al.  Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial , 2021, The Lancet Infectious Diseases.

[19]  M. Kirchhof,et al.  An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology , 2021, Journal of the American Academy of Dermatology.

[20]  Reza Zolfaghari Emameh,et al.  Identification and characterization of a silent mutation in RNA binding domain of N protein coding gene from SARS-CoV-2 , 2021, BMC research notes.

[21]  C. Demirdover.  COVID-19-vaccines , 2021, Reactions Weekly.

[22]  J. Gargano,et al.  The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020 , 2021, MMWR. Morbidity and mortality weekly report.

[23]  J. Abril,et al.  Host-dependent editing of SARS-CoV-2 in COVID-19 patients , 2021, Emerging microbes & infections.

[24]  A. Koyanagi,et al.  Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of in vitro, in vivo, and clinical trials , 2021, Theranostics.

[25]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[26]  Nguyen H. Tran,et al.  Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.

[27]  Elisabeth Mahase.  Covid-19: Moderna applies for US and EU approval as vaccine trial reports 94.1% efficacy , 2020, BMJ.

[28]  Shibo Jiang,et al.  Learning from the past: development of safe and effective COVID-19 vaccines , 2020, Nature Reviews Microbiology.

[29]  A. Prakash,et al.  In Silico Structure-Based Repositioning of Approved Drugs for Spike Glycoprotein S2 Domain Fusion Peptide of SARS-CoV-2: Rationale from Molecular Dynamics and Binding Free Energy Calculations , 2020, mSystems.

[30]  L. Rostaing,et al.  Impact of Circulating SARS-CoV-2 Mutant G614 on the COVID-19 Pandemic. , 2020, Iranian journal of kidney diseases.

[31]  Xuguang Li,et al.  The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity , 2020, Cell.

[32]  Ashutosh Kumar Singh,et al.  A Comprehensive Review of Animal Models for Coronaviruses: SARS-CoV-2, SARS-CoV, and MERS-CoV , 2020, Virologica Sinica.

[33]  C. Page,et al.  Animal models of mechanisms of SARS‐CoV‐2 infection and COVID‐19 pathology , 2020, British journal of pharmacology.

[34]  Shibo Jiang,et al.  Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2. , 2020, Antiviral research.

[35]  Shibo Jiang,et al.  Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2 , 2020, Antiviral Research.

[36]  Eriko Padron-Regalado.  Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains , 2020, Infectious Diseases and Therapy.

[37]  A. Mentis,et al.  SARS-CoV-2 exhibits intra-host genomic plasticity and low-frequency polymorphic quasispecies , 2020, bioRxiv.

[38]  A. Prakash,et al.  COVID-19 pandemic: A review based on current evidence , 2020, Indian journal of pharmacology.

[39]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[40]  Shibo Jiang,et al.  Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses , 2020, Frontiers in Microbiology.

[41]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[42]  Fang Li,et al.  Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry , 2019, Journal of Virology.

[43]  Stephen J. Thomas,et al.  A review of Dengvaxia®: development to deployment , 2019, Human vaccines & immunotherapeutics.

[44]  J. E. Muñoz-Medina,et al.  Cross-Reaction, Enhancement, and Neutralization Activity of Dengue Virus Antibodies against Zika Virus: A Study in the Mexican Population , 2019, Journal of immunology research.

[45]  Christine Nardini,et al.  Vaccination in the elderly: The challenge of immune changes with aging. , 2018, Seminars in immunology.

[46]  Edith Jasny,et al.  New Vaccine Technologies to Combat Outbreak Situations , 2018, Front. Immunol..

[47]  Shibo Jiang,et al.  Prospects for a MERS-CoV spike vaccine , 2018, Expert review of vaccines.

[48]  Siobain Duffy,et al.  Why are RNA virus mutation rates so damn high? , 2018, PLoS biology.

[49]  A. Lauring,et al.  Influenza A(H7N9) Virus Evolution: Which Genetic Mutations Are Antigenically Important? , 2018, Journal of Infectious Diseases.

[50]  A. Brault,et al.  Zika Virus Shedding in Semen of Symptomatic Infected Men , 2018, The New England journal of medicine.

[51]  Nikos,et al.  Adverse birth outcomes associated with Zika virus exposure during pregnancy in São José do Rio Preto, Brazil. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[52]  A. García-Sastre,et al.  Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity , 2017, Science.

[53]  B. Haynes,et al.  Developing an HIV vaccine , 2017, Science.

[54]  J. Leask,et al.  The impact of a vaccine scare on parental views, trust and information needs: a qualitative study in Sydney, Australia , 2017, BMC Public Health.

[55]  S. Munir Alam,et al.  Antibody‐virus co‐evolution in HIV infection: paths for HIV vaccine development , 2017, Immunological reviews.

[56]  M. V. Van Regenmortel,et al.  Structure-Based Reverse Vaccinology Failed in the Case of HIV Because it Disregarded Accepted Immunological Theory , 2016, International journal of molecular sciences.

[57]  Christopher Dye,et al.  Zika Virus and the Guillain-Barré Syndrome - Case Series from Seven Countries. , 2016, The New England journal of medicine.

[58]  Dennis R Burton,et al.  Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design. , 2016, Annual review of immunology.

[59]  N. Hynes,et al.  The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model , 2016, Science Translational Medicine.

[60]  K. Vainio,et al.  Stability of a Vesicular Stomatitis Virus-Vectored Ebola Vaccine. , 2016, The Journal of infectious diseases.

[61]  P. Formenty,et al.  Systematic review of the literature on viral persistence and sexual transmission from recovered Ebola survivors: evidence and recommendations , 2016, BMJ Open.

[62]  B. Pulendran,et al.  Signatures in Simian Immunodeficiency Virus SIVsmE660 Envelope gp120 Are Associated with Mucosal Transmission but Not Vaccination Breakthrough in Rhesus Macaques , 2015, Journal of Virology.

[63]  P. Schuster,et al.  What Is a Quasispecies? Historical Origins and Current Scope. , 2015, Current topics in microbiology and immunology.

[64]  D. Burton,et al.  Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design. , 2015, Immunity.

[65]  S. Vasudevan,et al.  Animal models for studying dengue pathogenesis and therapy. , 2015, Antiviral research.

[66]  K. Subbarao,et al.  Influenza vaccines: challenges and solutions. , 2015, Cell host & microbe.

[67]  J. Spouge,et al.  Conserved Molecular Signatures in gp120 Are Associated with the Genetic Bottleneck during Simian Immunodeficiency Virus (SIV), SIV-Human Immunodeficiency Virus (SHIV), and HIV Type 1 (HIV-1) Transmission , 2015, Journal of Virology.

[68]  J. de Pina-Cabral,et al.  World , 2014, HAU: Journal of Ethnographic Theory.

[69]  J. McElhaney,et al.  Immunosenescence: Influenza vaccination and the elderly. , 2014, Current opinion in immunology.

[70]  Youn-Jeong Lee,et al.  New vaccines against influenza virus , 2013, Clinical and experimental vaccine research.

[71]  S. Reed,et al.  Key roles of adjuvants in modern vaccines , 2013, Nature Medicine.

[72]  A. Vincent,et al.  Vaccine-Induced Anti-HA2 Antibodies Promote Virus Fusion and Enhance Influenza Virus Respiratory Disease , 2013, Science Translational Medicine.

[73]  N. Andrews,et al.  Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis , 2013, BMJ : British Medical Journal.

[74]  Theo M Bestebroer,et al.  Airborne Transmission of Influenza A/H5N1 Virus Between Ferrets , 2012, Science.

[75]  Harish Nair,et al.  Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis , 2011, The Lancet.

[76]  K. Mansfield,et al.  International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. , 2011, Vaccine.

[77]  J. Taubenberger,et al.  Influenza virus evolution, host adaptation, and pandemic formation. , 2010, Cell host & microbe.

[78]  D. Barouch,et al.  Challenges in the development of an HIV-1 vaccine , 2008, Nature.

[79]  J. Mascola,et al.  A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial , 2008, Vaccine.

[80]  S. Higgs,et al.  A Single Mutation in Chikungunya Virus Affects Vector Specificity and Epidemic Potential , 2007, PLoS pathogens.

[81]  Y. Kawaoka,et al.  Epitopes required for antibody-dependent enhancement of Ebola virus infection. , 2007, The Journal of infectious diseases.

[82]  Yee‐Shin Lin,et al.  The Dual-Specific Binding of Dengue Virus and Target Cells for the Antibody-Dependent Enhancement of Dengue Virus Infection1 , 2006, The Journal of Immunology.

[83]  A. Lapedes,et al.  Mapping the Antigenic and Genetic Evolution of Influenza Virus , 2004, Science.

[84]  J. Hansen,et al.  Increased adhesion as a mechanism of antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus infection , 1995, Journal of virology.

[85]  Katherine Spindler,et al.  Rapid evolution of RNA genomes. , 1982, Science.

[86]  R. Douglas,et al.  Effect of route of inoculation on experimental respiratory viral disease in volunteers and evidence for airborne transmission , 1966 .

[87]  R B Couch,et al.  Effect of route of inoculation on experimental respiratory viral disease in volunteers and evidence for airborne transmission. , 1966, Bacteriological reviews.

[88]  R. Hawkes,et al.  ENHANCEMENT OF THE INFECTIVITY OF ARBOVIRUSES BY SPECIFIC ANTISERA PRODUCED IN DOMESTIC FOWLS. , 1964, The Australian journal of experimental biology and medical science.

[89]  M. McGowan.  The Council , 1963 .

[90]  A. Blenkinsop,et al.  World Health , 1957, Nature.

[91]  H. Lei,et al.  Antibody-dependent enhancement in dengue virus infection. , 2008 .

[92]  K. Yoon,et al.  Antibody-dependent enhancement of virus infection and disease. , 2003, Viral immunology.